Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Conformis, Inc. (CFMS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.7100-0.0400 (-1.45%)
At close: 04:00PM EST
2.8500 +0.14 (+5.17%)
After hours: 07:20PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.7500
Open2.7600
Bid2.5100 x 1300
Ask2.8500 x 1200
Day's Range2.6600 - 2.8300
52 Week Range1.2000 - 18.7750
Volume30,379
Avg. Volume132,494
Market Cap504.32M
Beta (5Y Monthly)1.29
PE Ratio (TTM)N/A
EPS (TTM)-0.3400
Earnings DateFeb 28, 2023 - Mar 06, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.42
  • GlobeNewswire

    Conformis, Inc. to Announce Financial Results for Its Fourth Quarter and Full-Year 2022

    BILLERICA, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the fourth quarter and full-year ended December 31, 2022, after the market closes on Wednesday, March 1, 2023. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide a b

  • GlobeNewswire

    Conformis, Inc. Regains Compliance with Nasdaq’s Minimum Bid Price Rule

    BILLERICA, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it received a letter from the Listing Qualifications Department of The NASDAQ Stock Market (“NASDAQ”) on November 25, 2022 notifying Conformis that, based on the closing bid price of Conformis’ common stock having been $1.00 per share or greater on each of the trading days from November 10, 2022 to November 23, 2022, Conformis has regained compliance with Nasdaq Listing Rule 5550(a)(2) and the

  • GlobeNewswire

    Conformis Announces First Procedure Performed Using New Actera™ Hip System

    First Actera™ procedure underscores company’s ongoing commitment to advancing joint replacement technology by leveraging its data-driven approach and surgical planning expertiseBILLERICA, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, today announced that the first procedure with the company’s new Actera™ Hip System has been performed. Dr. William Kurtz, MD performed the hip re

Advertisement
Advertisement